title: Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Behçet's disease.
abstract: OBJECTIVE
  To evaluate the efficacy of measuring subfoveal choroidal thickness in monitoring uveitis activity before and after treatment with infliximab in patients with Behçet's disease (BD)-associated uveitis.
  
  
  METHODS
  Thirteen patients with BD (23 eyes) were selected for this retrospective observational case study. Subfoveal choroidal thickness was measured during active and remission phases of uveitis by enhanced depth imaging-spectral domain optical coherence tomography (EDI-OCT). In five patients (10 eyes), choroidal thickness was assessed at weeks 0, 2, 6 and 14 after the initiation of infliximab treatment.
  
  
  RESULTS
  Accompanied by excessive dye leakage from choroidal vessels on indocyanine green angiography, dilation of choroidal vessels was observed in the active phase of uveitis by EDI-OCT and the choroidal thickness was significantly greater than that in the remission phase. Treatment with infliximab significantly reduced the choroidal thickness from week 2 after the first infusion, and the reduced choroidal thickness was maintained thereafter. No correlation was found between choroidal thickness and best corrected visual acuity converted to logarithm of the minimum angle of resolution, but choroidal thickness correlated significantly with anterior and posterior ocular inflammation scores.
  
  
  CONCLUSIONS
  This study indicates that measurement of subfoveal choroidal thickness by EDI-OCT is useful for evaluating the activity of uveitis and the therapeutic efficacy in patients with BD.
authors.affiliation: Department of Ophthalmology, National Defense Medical College, Saitama, Japan.
authors.forename: Sho
authors.initials: S
authors.lastname: Ishikawa
authors.affiliation: Department of Ophthalmology, National Defense Medical College, Saitama, Japan.
authors.forename: Manzo
authors.initials: M
authors.lastname: Taguchi
authors.affiliation: Department of Ophthalmology, National Defense Medical College, Saitama, Japan.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Muraoka
authors.affiliation: Department of Ophthalmology, National Defense Medical College, Saitama, Japan.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Sakurai
authors.affiliation: Department of Ophthalmology, National Defense Medical College, Saitama, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kanda
authors.affiliation: Department of Ophthalmology, National Defense Medical College, Saitama, Japan.
authors.forename: Masaru
authors.initials: M
authors.lastname: Takeuchi
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D002199:Capillary Permeability; D002829:Choroid / Q000098:blood supply / Q000473:pathology*; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D007208:Indocyanine Green; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D015866:Uveitis, Posterior / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D014792:Visual Acuity
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D004396:Coloring Agents; D000069285:Infliximab; D007208:Indocyanine Green
keywords: Imaging; Inflammation